Pine Valley Investments Ltd Liability Co Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Pine Valley Investments Ltd Liability Co increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 66.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,568 shares of the medical device company’s stock after purchasing an additional 1,430 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in DexCom were worth $405,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in DexCom during the 4th quarter worth approximately $1,986,000. Atria Wealth Solutions Inc. grew its holdings in DexCom by 73.9% during the fourth quarter. Atria Wealth Solutions Inc. now owns 6,290 shares of the medical device company’s stock worth $781,000 after acquiring an additional 2,674 shares during the period. Gilbert & Cook Inc. raised its position in DexCom by 8.2% in the fourth quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock worth $426,000 after acquiring an additional 261 shares in the last quarter. First Trust Direct Indexing L.P. lifted its holdings in DexCom by 16.7% in the fourth quarter. First Trust Direct Indexing L.P. now owns 9,920 shares of the medical device company’s stock valued at $1,231,000 after acquiring an additional 1,418 shares during the period. Finally, 9258 Wealth Management LLC purchased a new stake in shares of DexCom during the 4th quarter worth $286,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Down 0.4 %

DXCM traded down $0.28 during trading on Friday, reaching $69.34. 4,614,225 shares of the stock traded hands, compared to its average volume of 3,777,717. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock’s 50-day simple moving average is $90.92 and its two-hundred day simple moving average is $114.58. The stock has a market cap of $27.58 billion, a price-to-earnings ratio of 44.74, a price-to-earnings-growth ratio of 2.18 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the firm earned $0.34 EPS. DexCom’s revenue for the quarter was up 15.3% on a year-over-year basis. As a group, equities research analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Activity

In related news, CFO Jereme M. Sylvain sold 745 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the sale, the chief financial officer now directly owns 84,948 shares in the company, valued at approximately $9,773,267.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Jereme M. Sylvain sold 745 shares of DexCom stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the transaction, the chief financial officer now owns 84,948 shares in the company, valued at approximately $9,773,267.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,483 shares of company stock valued at $369,052. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on DXCM shares. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Royal Bank of Canada lowered their target price on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Redburn Atlantic initiated coverage on DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Barclays decreased their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Finally, Oppenheimer lowered their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.